• Skip to content
  • Skip to footer
  • Français

RIC Centre

We help tech entrepreneurs fast-track their business to market

Main navigation

  • Who We Are
    • About RIC Centre
    • Our Impact
    • Team
    • Advisors
    • Incubator Clients
    • Community Partners
  • What we do
    • Pre-Revenue Startups
    • Post-Revenue Startups
    • Corporate Intrapreneurship
    • Core Services
    • Incubator
  • Success Stories
  • What’s Happening
    • News and Insights
    • Blog
    • Events
    • Monthly Digest
  • GET IN TOUCH
  • JOIN RIC CENTRE

August 8, 2011 By RIC Centre

MicroRNAs and Neutral Lipid Emulsion – Therapeutic Approach for Lung Cancer Treatment

Monika L. Ignacak 

According to Statistics Canada lung cancer is the second most common cancer affecting Canadians. An estimated 25,300 new cases of lung cancer are expected in 2011, with 8,000 new cases diagnosed in Ontario.

Since current therapies fail to cure lung cancer, novel therapies are needed to effectively treat people.  Lately, miRNAs have emerged as promising therapeutic, but there are challenges delivering potential drug to cancer cells. In an attempt to resolve this problem, Dr. Trang and Dr. Slack from Yale University used new neutral lipid emulsion (NLE) to deliver synthetic microRNA (miRNA) mimics to non-small cell lung cancer (NSCLC).

MiRNAs are small RNAs which negatively regulate gene expression in cells and are involved in many processes important for normal cell functioning. These small RNAs are often misexpressed or damaged in tumor cells. MiRNAs let-7 and miR-34a, the two oncogenesis-associated miRNAs, are lost in lung cancer. To restore the miRNAs’ function in tumor cells, scientist used neutral lipid emulsion to deliver miRNAs to the cancer cells. NLE was mixed with synthetic let-7 or miR-34a mimics and injected into genetically modified
mice developing NSCLC (K-ras autochtonous NSCLC mouse model). Scientists observed reduced cancer cell proliferation and substantial decrease in tumor size in both groups and additionally increased apoptosis in tumor cells in group treated with miR-34a.

Neutral lipid emulsion from BIO Scientific (Austin, Texas) known as MaxSuppressor in vivo RNA-LANCEr II has a unique composition based on neutral lipids, which assure efficient delivery to tissues and is less toxic in comparison to cationic lipid delivery agents. The results presented by Dr. Trang and Dr. Slack promise the new targeted therapy for lung cancer.

Journal Reference:
Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice.Trang P, Wiggins JF, Daige CL, Cho C, Omotola M, Brown D, Weidhaas JB, Bader AG, Slack FJ. Mol Ther. 2011 Jun;19(6):1116-22.

Monika L. Ignacak

has Ph.D. in Molecular Biology and experience in molecular neuroscience and molecular biology of steroid hormones from the Poznan University of Medical Sciences and the University of Cincinnati. Currently she works at the RIC Center, where she is involved in developing effective data organizing system.
 

The RIC blog is designed as a showcase for entrepreneurs and innovation. Our guest bloggers provide a wealth of information based on their personal experiences. Visit RIC Centre for more information on how RIC can accelerate your ideas to market.

Filed Under: Blog

Connect for Entrepreneur and Innovation Support

  • Facebook
  • Linkedin
  • Twitter
  • YouTube

Footer

Contact Us

RIC Centre is co-located with the Xerox Research Centre of Canada

RIC Centre
2660 Speakman Dr
Mississauga, ON
L5K 2L1

Register Now for Entrepreneur Support

In order to access the RIC Centre’s free services for technology entrepreneurs, complete the registration and intake process starting with this form. You will then be contacted within approximately 2-3 business days to arrange a brief phone call so we can evaluate your needs and determine the best way to move forward.

Join RIC Centre »

Connect With Us

Entrepreneur & Innovation Support

  • Facebook
  • Linkedin
  • Twitter
  • YouTube

one-logo-englishone-logo-francais